Drug maker Pfenex has announced positive top-line results from a phase 3 study that showed comparable overall profiles between reference teriparatide (Forteo) and Pfenex’s proposed follow-on, PF708, in patients with osteoporosis. Teriparatide, a recombinant human parathyroid hormone, is an anabolic agent that stimulates bone formation.
Drug maker Pfenex has announced positive top-line results from its phase 3 PF708-301 study, which showed comparable overall profiles between reference teriparatide (Forteo) and Pfenex’s proposed follow-on, PF708, in patients with osteoporosis. Teriparatide, a recombinant human parathyroid hormone, is an anabolic agent that stimulates bone formation.
The study enrolled 181 patients with osteoporosis who were randomized to receive either the proposed follow-on or the reference Forteo. In total, 82 patients in the follow-on arm and 81 patients in the reference arm completed the 24-week study.
The primary study endpoint was incidence of anti-drug antibodies (ADAs) at 24 weeks of treatment, and secondary endpoints included the mean percentage changes in lumbar-spine bone mineral density (BMD) and median percentage changes in bone turnover markers after 24 weeks, as well as pharmacokinetic parameters for up to 4 hours after the first dose. Safety was also assessed, using the incidence of adverse events (AEs).
In total, 2 patients in the follow-on arm and 2 patients in the reference arm developed ADAs during the study period, and “these low rates of immunogenicity are consistent with historical Forteo results,” as well as “with observations in follow-on biologics and biosimilars approved in the United States,” says the company.
The follow-on and reference teriparatide demonstrated comparable effects, with no statistically significant differences observed, on lumbar spine BMD and on both N-terminal propeptide of type 1 procollagen (a marker of bone formation) and cross-linked C-terminal telopeptide of type 1 collagen (a marker of bone reabsorption).
Pfenex also reported that there were no significant differences in the proportion of patients who experienced AEs, or in the severity of AEs, between the 2 study arms.
While teriparatide follow-on products are regulated as biosimilars in the European Union (and biosimilars including Gedeon Richter’s Terrosa and Stada’s Movymia have already been approved for marketing), in the United States, they are regulated as drugs. As such, Pfenex will submit to the FDA a New Drug Application (NDA), rather than a Biologics License Application, for PF708. Pfenex says it will submit its NDA in the third quarter of 2018.
Other drugs in Pfenex’s follow-on and biosimilars pipeline include ranibizumab (referencing Lucentis), pegfilgrastim (referencing Neulasta), and Pegaspargase (referencing Oncaspar). The company is also developing novel anthrax vaccine candidates, funded by HHS, in an effort to meet the US government’s demand for dose-sparing anthrax vaccines.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Risk-Adjusted NPV Framework for Biosimilars Shows Key Investment Drivers
April 7th 2025Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, while technical complexity and competition heavily impact returns, according to a study presenting a risk-adjusted net present value (NPV) analysis framework.